SciBase Holding Appoints Nomination Committee for Upcoming AGM in 2027

SciBase Holding's Nominating Committee Announcement for 2027 AGM



In preparation for its Annual General Meeting (AGM) set for May 20, 2027, SciBase Holding AB announced the appointment of a new nominating committee. This committee is crucial for ensuring the oversight and governance of the upcoming meeting, especially with significant advancements in the company's portfolio.

The members that have been appointed to this committee include:
  • - Anders Bladh from Ribbskottet AB
  • - Derek Maetzold from Castle Biosciences Inc
  • - Maria Anderkvist from Coeli Wealth Management
  • - Jesper Høiland, who serves as the Chairman of the Board.

These appointments were established based on the guidelines set during the previous AGM held on May 19, 2026. The newly formed committee will play a pivotal role in shaping discussions and recommendations leading up to the AGM, which will occur in Stockholm, Sweden.

Shareholders have the opportunity to influence the agenda of the meeting. Those wishing to submit proposals for topics to be considered by the nominating committee ought to send their requests in writing to SciBase Holding at the address of the Chairman of the Board. It's vital that these submissions reach the Board no later than seven weeks before the AGM. This proactive step ensures that significant issues affecting stakeholders and corporate strategy can be included in the meeting agenda.

SciBase Holding AB is renowned for its dedication to innovative medical technology, with a strong focus on early detection in dermatology. The company’s flagship product, Nevisense, leverages advanced AI and Electrical Impedance Spectroscopy (EIS) technology to improve diagnostic accuracy for skin health. By minimizing patient suffering and reducing healthcare costs through early detection, SciBase demonstrates a commitment to enhancing life quality.

Founded on extensive research conducted at the Karolinska Institute over the past two decades, SciBase is recognized as a leader in dermatological advancements and has been publicly traded since June 2, 2015, on the Nasdaq First North Growth Market.

For further inquiries regarding the AGM or the nomination committee, interested parties can contact:
  • - Jesper Høiland (Chairman of the Board) at +45 612 207 30
  • - Michael Colérus (CFO) at +46 70 341 34 72

Potential investors and those interested in the company’s financial health can also refer to the company’s certified advisor, DNB Carnegie Investment Bank AB, for additional support.

For more information about SciBase and its board, shareholders and interested parties can visit SciBase’s official website and follow their investor relations page for the latest press releases and financial reports.

As the industry faces constant challenges and innovations, SciBase Holding’s appointments signal a robust approach to governance and stakeholder engagement for the upcoming AGM in 2027.

  • ---
This announcement highlights the importance of strategic leadership in navigating the company's future within the evolving landscape of healthcare technology.

Topics Business Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.